Clumping factor A

Identifiers
Organism| Staphylococcus aureus
Symbol| clfA
RefSeq (Prot)| WP_001056178.1
UniProt| Q53653
Other data
Chromosome| Genomic: 0.85 - 0.85 Mb
| Search for

Structures| Swiss-model
Domains| InterPro

Clumping factor A is a major virulence factor and a protein from Staphylococcus aureus.[1] It plays a role in several types of infections, such as infective endocarditis, septic arthritis, kidney abscesses, and sepsis/septicemia.[2] ClfA binds to the fibrinogen protein in blood plasma, allowing the bacteria to stick to platelets and begin creating blood clots(thrombus). ClfA binding to fibrinogen is essential in thrombus formation.[3] Fibrinogen is a protein that is made of three pairs of non identical polypeptide chains. It is then broken down by thrombin during blood coagulation, which releases a fibrin monomer. These monomers combine to make a network that gives tensile strength to a blood clot. These fibrin clots are the substrate of the fibrinolytic system.[4]

ClfA also has been shown to bind to complement regulator I protein.[5]

## Contents

* 1 History and discovery
* 2 Protein mechanism
* 3 Immune system evasion
* 4 Structure
* 4.1 ClfA structure
* 4.1.1 Human fibrinogen structure
* 5 Biological functions
* 5.1 Bacterial adhesion by fibrinogen binding
* 5.1.1 Biofilm formation on tissues and medical devices
* 5.1.1.1 Inhibitory activities of antibodies against ClfA
* 6 Medical relevance
* 6.1 Biofilm formation health effects
* 7 See also
* 8 References

## History and discovery

Staphylococcus aureus was first described in 1880 by Sir Alexander Ogston from a surgical abscess in a knee joint.[citation needed] The S. aureus strain Newman is where Clumping factor A was first identified.[6]

## Protein mechanism

ClfA is a surface protein that is anchored to the wall of S. aureus and belongs to the MSCRAMM family, which helps bind bacteria to host extracellular or plasma proteins. Its primary binding partner is the C-terminal region of the γ-chain of fibrinogen. Research shows that the strength of the ClfA–fibrinogen interaction depends heavily on mechanical force. Under low mechanical tension or low shear stress, the interaction is relatively weak, measuring around ~0.1 nN. However, when exposed to high mechanical force, the binding strength increases dramatically to approximately ~1.5 nN.[7] This behavior represents a classic catch-bond mechanism, in which the application of force enhances, rather than disrupts, the stability of a ligand–receptor interaction.[7]

The study further suggests that ClfA contains two distinct binding sites for fibrinogen: a low-affinity site that operates under minimal force and a high-affinity site that becomes engaged when mechanical stress is greater. At a low force, it is suggested that fibrinogen may bind near the top of the N3 domain. [7] While further research needs to be done, these findings indicate that ClfA is mechanically regulated, which allows S. aureus to strengthen adhesion as sheer stress increases, such as during blood flow or when interacting with medical devices like pacemakers and catheters.

## Immune system evasion

ClfA contributes to immune evasion through several complementary mechanisms. By binding fibrinogen and fibrin, ClfA covers bacterial surface antigens that would normally be recognized by immune cells. This “masking” effect prevents efficient opsonization and inhibits phagocyte binding.[8] In addition to steric shielding, ClfA-induced bacterial aggregation forms large clumps that are physically more difficult for neutrophils and macrophages to take over.

ClfA also interacts with complement factor I, which is an enzyme responsible for cleaving C3b into its inactive form, iC3b. When factor I is recruited to the bacterial surface through ClfA, it inactivates complement proteins, reducing opsonization and preventing the assembly of the membrane attack complex. [8]

## Structure

Human Fibrinogen Structure

### ClfA structure

The ClfA structure contains a ligand-binding region, labeled as the A region, which is composed of three subdomains (N1, N2, N3). [9] The secondary structure contains beta pleated sheets and short alpha helices. The tertiary structure is the three-domain A region (N1, N2, and N3).[9]

#### Human fibrinogen structure

The primary structure of fibrinogen is composed of three pairs of polypeptide chains that are held together by disulfide-bridged Aα‐, Bβ‐, and γ‐chains near the N-terminus.[10] The secondary structure contains alpha helices as well as beta pleated sheets. The tertiary structure folds into three different domains: the folded E domain, which contains fibrinopeptides A and B that thrombin cleaves during blood clotting, the D domain, where the γ-chain C-terminus contains the binding site for ClfA, and a connecter region, which is the middle section of the molecule that links the N-terminal to the C-terminal domains of each chain. [10]

## Biological functions

### Bacterial adhesion by fibrinogen binding

Clumping factor A’s main function is to bind the host blood plasma proteins fibrinogen(fg), specifically the extreme C-terminal region of the fibrinogen γ chain.[11] ClfA also acts as a force-sensitive molecular switch, meaning under physiological stress, like blood flow, the binding between fibrinogen and ClfA becomes stronger. This is because of a catch bond behaviour that allows S. aureus to remain stuck under high mechanical stress; this function is critical in blood vessels.[12]

#### Biofilm formation on tissues and medical devices

Staphylococcus biofilm on a catheter

Clumping factor A facilitates biofilm formation by binding to host fibrinogen, allowing S. aureus bacterium to attach to surfaces like medical devices and damaged tissues.[13] Once attached, the bacteria proliferate and produce an extracellular matrix, ultimately forming a biofilm that shields them from antibiotics and the host's immune response. As a result, antibodies directed against clumping factor A should be explored as a potential strategy to disrupt biofilm formation. During blood flow, ClfA also allows S. aureus to bind to vascular endothelial cells, which contributes to infection in blood vessels.[14] One of the leading causes of infections inside blood vessels is from S. aureus. ClfA also serves as the bacterial partner fo von Willebrand factor-binding protein (vWbp), which is another protein that is found in the blood stream. ClfA helps S. aureus attach to the walls of blood vessels during blood flow by binding to vWbp which then connects to the von Willebrand factor (VWF).[14]

##### Inhibitory activities of antibodies against ClfA

ClfA interacts with a wide range of ligands, and these interactions increase the ability of S. aureus to proliferate in the bloodstream. Fibrin is an example of one of these ligands, which ClfA binds to, functioning as the key agglutinating factor that helps the bacteria escape phagocytes. Phagocytes are white blood cells that protect the body by ingesting bacteria, cellular debris, and other harmful particles through a process called phagocytosis. As key components of the innate immune system, they serve as one of the body’s first lines of defense against infection.[15]One study found that antibodies that inhibited ClfA interactions with ligands reduced bacterial infections in animals.[16] The same study found that the interaction of fibrinogen and ClfA contributed to the virulence of S. aureus because of a complement-mediated mechanism. [17] ClfA can also bind serum factor I, an enzyme that breaks down complement protein C3b in the immune system. Then factor I comes to the surface of S. aureus, it converts C3b into an inactive form called iC3b. These findings provided a likely mechanism for how the S. aureus bacterium can evade the complement-mediated immune defences.[17]

## Medical relevance

Clumping Factor A (ClfA) is a key target for anti-S. aureus treatments due to its strong role as a virulence factor. Pfizer chose ClfA as a component for a multivalent vaccine.[18] Preclinical research demonstrated that ClfA protects against murine models of arthritis, sepsis, and endocarditis. A recent study using a mouse mastitis model found that targeting both the CP5 and ClfA antigens which reduced bacterial infections. ClfA was then evaluated in studies with Veronate derived from a pool of donor-selected human IgG, or immunoglobulin G. Although there was promising preclinical research, Veronate did not reduce the incidence of Staphylococcus sepsis in neonates.[18]

### Biofilm formation health effects

Biofilms can survive and bacteria can replicate under very harsh conditions and have increased resistance to physical and chemical stress. Biofilms are incredibly common because of their adaptability and make up roughly 40-80% of all bacterial communities on Earth[19] Since they have a high ability to develop resistance reactions, there is a growing number of many difficult to treat infections such as urinary tract infections, catheters, and medical devices.[19] It was found in an animal infection model that anti-ClfA antibodies protected against biofilm-associated infections.[13]

## See also

* Tefibazumab
* Coagulase

## References

1. ↑ Herman-Bausier, Philippe; Labate, Cristina; Towell, Aisling M.; Derclaye, Sylvie; Geoghegan, Joan A.; Dufrêne, Yves F. (2018-05-22). "Staphylococcus aureus clumping factor A is a force-sensitive molecular switch that activates bacterial adhesion". Proceedings of the National Academy of Sciences of the United States of America 115 (21): 5564–5569. doi:10.1073/pnas.1718104115. PMID 29735708. Bibcode: 2018PNAS..115.5564H.
2. ↑ Ganesh, Vannakambadi K.; Liang, Xiaowen; Geoghegan, Joan A.; Cohen, Ana Luisa V.; Venugopalan, Nagarajan; Foster, Timothy J.; Hook, Magnus (November 2016). "Lessons from the Crystal Structure of the S. aureus Surface Protein Clumping Factor A in Complex With Tefibazumab, an Inhibiting Monoclonal Antibody". eBioMedicine 13: 328–338. doi:10.1016/j.ebiom.2016.09.027. PMID 27789272.
3. ↑ "Staphylococcus aureus Clumping Factor Mediates Rapid Thrombus Formation under High Shear". Blood 108 (11): 1816. 2006. doi:10.1182/blood.V108.11.1816.1816.
4. ↑ "FIBRINOLYSIS | Overview". Encyclopedia of Respiratory Medicine. 2006. pp. 201–205. doi:10.1016/B0-12-370879-6/00153-8. ISBN 978-0-12-370879-3. "Fibrin monomers polymerize into an insoluble network that gives tensile strength to the blood clot and is the substrate of the fibrinolytic system."
5. ↑ "Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b". The Journal of Infectious Diseases 198 (1): 125–133. July 2008. doi:10.1086/588825. PMID 18544012.
6. ↑ Siboo, I. R.; Cheung, A. L.; Bayer, A. S.; Sullam, P. M. (May 2001). "Clumping factor A mediates binding of Staphylococcus aureus to human platelets". Infection and Immunity 69 (5): 3120–3127. doi:10.1128/IAI.69.5.3120-3127.2001. PMID 11292731.
7. ↑ 7.0 7.1 7.2 Herman-Bausier, Philippe; Labate, Cristina; Towell, Aisling M.; Derclaye, Sylvie; Geoghegan, Joan A.; Dufrêne, Yves F. (2018-05-22). "Staphylococcus aureus clumping factor A is a force-sensitive molecular switch that activates bacterial adhesion". Proceedings of the National Academy of Sciences of the United States of America 115 (21): 5564–5569. doi:10.1073/pnas.1718104115. PMID 29735708. Bibcode: 2018PNAS..115.5564H.
8. ↑ 8.0 8.1 Hair, Pamela S.; Echague, Charlene G.; Sholl, Amber M.; Watkins, Justin A.; Geoghegan, Joan A.; Foster, Timothy J.; Cunnion, Kenji M. (April 2010). "Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis". Infection and Immunity 78 (4): 1717–1727. doi:10.1128/IAI.01065-09. PMID 20100856.
9. ↑ 9.0 9.1 Herman-Bausier, Philippe; Labate, Cristina; Towell, Aisling M.; Derclaye, Sylvie; Geoghegan, Joan A.; Dufrêne, Yves F. (2018-05-22). "Staphylococcus aureus clumping factor A is a force-sensitive molecular switch that activates bacterial adhesion". Proceedings of the National Academy of Sciences of the United States of America 115 (21): 5564–5569. doi:10.1073/pnas.1718104115. PMID 29735708. Bibcode: 2018PNAS..115.5564H.
10. ↑ 10.0 10.1 "Fibrinogen and fibrin structure and functions". Journal of Thrombosis and Haemostasis 3 (8): 1894–1904. 2005. doi:10.1111/j.1538-7836.2005.01365.x. PMID 16102057.
11. ↑ Vazquez, Vanessa; Liang, Xiaowen; Horndahl, Jenny K.; Ganesh, Vannakambadi K.; Smeds, Emanuel; Foster, Timothy J.; Hook, Magnus (2011-08-26). "Fibrinogen Is a Ligand for the Staphylococcus aureus Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMM) Bone Sialoprotein-binding Protein (Bbp)" (in English). Journal of Biological Chemistry 286 (34): 29797–29805. doi:10.1074/jbc.M110.214981. PMID 21642438.
12. ↑ Herman-Bausier, Philippe; Labate, Cristina; Towell, Aisling M.; Derclaye, Sylvie; Geoghegan, Joan A.; Dufrêne, Yves F. (2018-05-22). "Staphylococcus aureus clumping factor A is a force-sensitive molecular switch that activates bacterial adhesion". Proceedings of the National Academy of Sciences of the United States of America 115 (21): 5564–5569. doi:10.1073/pnas.1718104115. PMID 29735708. Bibcode: 2018PNAS..115.5564H.
13. ↑ 13.0 13.1 Raafat, Dina; Otto, Michael; Reppschläger, Kevin; Iqbal, Jawad; Holtfreter, Silva (April 2019). "Fighting Staphylococcus aureus Biofilms with Monoclonal Antibodies". Trends in Microbiology 27 (4): 303–322. doi:10.1016/j.tim.2018.12.009. PMID 30665698.
14. ↑ 14.0 14.1 Claes, J.; Liesenborghs, L.; Peetermans, M.; Veloso, T. R.; Missiakas, D.; Schneewind, O.; Mancini, S.; Entenza, J. M. et al. (May 2017). "Clumping factor A, von Willebrand factor-binding protein and von Willebrand factor anchor Staphylococcus aureus to the vessel wall". Journal of Thrombosis and Haemostasis 15 (5): 1009–1019. doi:10.1111/jth.13653. PMID 28182324.
15. ↑ "Immunotoxicology Assessment in Drug Development". A Comprehensive Guide to Toxicology in Preclinical Drug Development. 2013. pp. 365–381. doi:10.1016/B978-0-12-387815-1.00014-9. ISBN 978-0-12-387815-1.
16. ↑ Banerjee, Biswarup; Emolo, Carla; Shi, Miaomiao; Al Fardan, Abrar Abdullah; Pius, Tonu; Azam, Muhammad Shafiul; McAdow, Molly; Schneewind, Olaf et al. (2025-09-08). "Inhibitory activities of monoclonal antibodies against Staphylococcus aureus clumping factor A". mBio 16 (10): e02197–25. doi:10.1128/mbio.02197-25. PMID 40919922.
17. ↑ 17.0 17.1 Hair, Pamela S.; Echague, Charlene G.; Sholl, Amber M.; Watkins, Justin A.; Geoghegan, Joan A.; Foster, Timothy J.; Cunnion, Kenji M. (April 2010). "Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis". Infection and Immunity 78 (4): 1717–1727. doi:10.1128/IAI.01065-09. PMID 20100856.
18. ↑ 18.0 18.1 Anderson, Annaliesa S.; Miller, Alita A.; Donald, Robert G. K.; Scully, Ingrid L.; Nanra, Jasdeep S.; Cooper, David; Jansen, Kathrin U. (2012-11-01). "Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors". Human Vaccines & Immunotherapeutics 8 (11): 1585–1594. doi:10.4161/hv.21872. PMID 22922765.
19. ↑ 19.0 19.1 Omwenga, Eric Omori; Awuor, Silas Onyango (2024). "The Bacterial Biofilms: Formation, Impacts, and Possible Management Targets in the Healthcare System". The Canadian Journal of Infectious Diseases & Medical Microbiology 2024. doi:10.1155/cjid/1542576. PMID 39717533.

* v
* t
* e

* Toxins
* enterotoxin
* neurotoxin
* hemotoxin
* cardiotoxin
* phototoxin

Bacterial
toxins|

| Exotoxin|

| Gram
positive|

| Bacilli|

| Clostridium:|

* tetani
* Tetanospasmin
* Tetanolysin
* perfringens
* Alpha toxin
* Enterotoxin
* difficile
* A
* B
* botulinum
* Botox

|

other:|

* Anthrax toxin
* Listeriolysin O

Cocci|

* Streptolysin
* Leukocidin
* Panton-Valentine leukocidin

Staphylococcus|

* Staphylococcus aureus alpha/beta/delta
* Exfoliatin
* Toxic shock syndrome toxin
* Staphylococcal Enterotoxin B (SEB)

Actinomycetota|

* Cord factor
* Diphtheria toxin

Gram
negative|

* Shiga toxin/Verotoxin
* E. coli heat-stable enterotoxin
* Cholera toxin/Heat-labile enterotoxin
* Pertussis toxin
* Pseudomonas exotoxin
* Extracellular adenylate cyclase

Mechanisms|

* type I
* Superantigen
* type II
* Pore-forming toxin
* type III
* AB toxin/AB5

Endotoxin|

* Lipopolysaccharide
* Lipid A
* Bacillus thuringiensis delta endotoxin
* Cry1Ac
* Cry3Bb1
* Other B. thuringiensis toxins
* Cry6Aa
* Cry34Ab1

Virulence
factor|

* Clumping factor A
* Fibronectin binding protein A

Mycotoxins|

* Aflatoxin
* Amatoxin (alpha-amanitin, beta-amanitin, gamma-amanitin, epsilon-amanitin)
* beta-Nitropropionic acid
* Citrinin
* Cytochalasin
* Ergotamine
* Fumonisin (Fumonisin B1, Fumonisin B2, Fumonisin B3, Fumonisin B4)
* Gliotoxin
* Ibotenic acid
* Lolitrem B
* Muscimol
* Ochratoxin
* Patulin
* Phalloidin
* Sterigmatocystin
* Trichothecene
* Vomitoxin
* Zeranol
* Zearalenone

Plant toxins|

* Amygdalin
* Anisatin
* Antiarin
* Brucine
* Chaconine
* Cicutoxin
* Daphnin
* Delphinine
* Divicine
* Djenkolic acid
* Falcarinol
* Gossypol
* Helenalin
* Ledol
* Linamarin
* Lotaustralin
* Mimosine
* Oenanthotoxin
* Oleandrin
* Persin
* Protoanemonin
* Pseudaconitine
* Retronecine
* Resiniferatoxin
* Scopolamine
* Solamargine
* Solanidine
* Solanine
* Solasodamine
* Solasodine
* Solasonine
* Solauricidine
* Solauricine
* Strychnine
* Swainsonine
* Tagetitoxin
* Tinyatoxin
* Tomatine
* Toxalbumin
* Abrin
* Ricin
* Tutin

Invertebrate
toxins|

| Scorpion:|

* Androctonus australis hector insect toxin
* Charybdotoxin
* Maurotoxin
* Agitoxin
* Margatoxin
* Slotoxin
* Scyllatoxin
* Hefutoxin
* HgeTx1
* HsTx1
* Lq2
* Birtoxin
* Bestoxin
* BmKAEP
* Phaiodotoxin
* Imperatoxin
* Pi3

|

spider:|

* Latrotoxin
* Alpha-latrotoxin
* CSTX
* Cupiennins
* PhTx3
* Stromatoxin
* Vanillotoxin
* Huwentoxin

Mollusca:|

* Conotoxin
* Eledoisin
* Onchidal
* Saxitoxin
* Tetrodotoxin

Vertebrate
toxins|

| Fish:|

* Ciguatera
* Tetrodotoxin

|

Amphibian:|

* (+)-Allopumiliotoxin 267A
* Batrachotoxin
* Bufotoxins
* Arenobufagin
* Bufotalin
* Bufotenin
* Cinobufagin
* Marinobufagin
* Epibatidine
* Histrionicotoxin
* Pumiliotoxin 251D
* Samandarin
* Samandaridine
* Tarichatoxin
* Zetekitoxin AB

Reptile/
Snake venom:|

* Bungarotoxin
* Alpha-Bungarotoxin
* Beta-Bungarotoxin
* Calciseptine
* Taicatoxin
* Calcicludine
* Cardiotoxin III

* note: some toxins are produced by lower species and pass through intermediate species

* Category

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Clumping factor A. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Clumping_factor_A&oldid=4321029"
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template